Similar articles for PMID: 30994530

Year	Number of Results
1991	1
1993	1
1995	4
1996	4
1997	2
1998	5
1999	2
2000	1
2002	2
2003	3
2004	3
2005	3
2006	5
2007	7
2008	7
2009	5
2010	1
2011	2
2012	2
2013	5
2014	4
2015	5
2016	6
2017	4
2018	4
2019	3
2020	1
2022	1
2024	0

1

cGMP manipulation in cardiometabolic disease: chances and challenges.

Jordan J, Hildebrand S, Pfeifer A. Jordan J, et al. Curr Opin Cardiol. 2019 Jul;34(4):376-383. doi: 10.1097/HCO.0000000000000630. Curr Opin Cardiol. 2019. PMID: 30994530 Review.

2

Genetics of NO Deficiency.

Leineweber K, Moosmang S, Paulson D. Leineweber K, et al. Am J Cardiol. 2017 Oct 15;120(8S):S80-S88. doi: 10.1016/j.amjcard.2017.06.013. Am J Cardiol. 2017. PMID: 29025574 Free article. Review.

3

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.

Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Lee DI, et al. Nature. 2015 Mar 26;519(7544):472-6. doi: 10.1038/nature14332. Epub 2015 Mar 18. Nature. 2015. PMID: 25799991 Free PMC article.

4

Regulation of metabolism by cGMP.

Pfeifer A, Kilić A, Hoffmann LS. Pfeifer A, et al. Pharmacol Ther. 2013 Oct;140(1):81-91. doi: 10.1016/j.pharmthera.2013.06.001. Epub 2013 Jun 10. Pharmacol Ther. 2013. PMID: 23756133 Review.

5

Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA.

Ying W, Zhao D, Ouyang P, Subramanya V, Vaidya D, Ndumele CE, Guallar E, Sharma K, Shah SJ, Kass DA, Hoogeveen RC, Lima JA, Heckbert SR, deFilippi CR, Post WS, Michos ED. Ying W, et al. J Am Heart Assoc. 2019 Dec 17;8(24):e013149. doi: 10.1161/JAHA.119.013149. Epub 2019 Dec 16. J Am Heart Assoc. 2019. PMID: 31838972 Free PMC article.

6

Meeting report: cGMP matters.

Kemp-Harper B, Feil R. Kemp-Harper B, et al. Sci Signal. 2008 Mar 4;1(9):pe12. doi: 10.1126/stke.19pe12. Sci Signal. 2008. PMID: 18319447

7

Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase.

Birschmann I, Walter U. Birschmann I, et al. Acta Biochim Pol. 2004;51(2):397-404. Acta Biochim Pol. 2004. PMID: 15218537 Free article. Review.

8

cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.

Dang TA, Schunkert H, Kessler T. Dang TA, et al. J Cardiovasc Pharmacol. 2020 Jun;75(6):516-525. doi: 10.1097/FJC.0000000000000744. J Cardiovasc Pharmacol. 2020. PMID: 32487847 Review.

9

Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.

Bice JS, Burley DS, Baxter GF. Bice JS, et al. J Cardiovasc Pharmacol Ther. 2014 May;19(3):269-82. doi: 10.1177/1074248413518971. Epub 2014 Feb 25. J Cardiovasc Pharmacol Ther. 2014. PMID: 24572031 Review.

10

C-type natriuretic peptide regulation of guanosine-3',5'-cyclic monophosphate production in human endothelial cells.

Rautureau Y, Gowers I, Wheeler-Jones CP, Baxter GF. Rautureau Y, et al. Auton Autacoid Pharmacol. 2010 Jul;30(3):185-92. doi: 10.1111/j.1474-8673.2009.00449.x. Epub 2010 Jan 19. Auton Autacoid Pharmacol. 2010. PMID: 20085572

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year